Skip to content

Tumor-tropic E. coli engineered as living T and NK cell engagers

Aug 2026 · bioRxiv · 0 citations
Biology

TL;DR

LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestration.

View source

Similar papers

Review Open access Sep 2026

When oncolytic viruses get on CAR: a synergic approach for solid tumor immunotherapy

Chimeric antigen receptor (CAR)-based cell therapies have transformed the treatment of selected hematologic malignancies, yet their efficacy in solid tumors remains limited due to antigen heterogeneity, inadequate trafficking, physical and metabolic barriers, immune suppression, and poor persistence of transferred cell...

Jia Li, Yan-Hong Shi · 0 citations
Open access Sep 2026

Adoptive MAIT cell therapy for liver cancer enhanced by multimodal modulation of immune receptors and checkpoints.

BACKGROUND Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that recognize riboflavin-derived metabolites presented by the monomorphic major histocompatibility complex (MHC)-class I-related molecule MR1. MAIT cells are highly enriched in the human liver and are increasingly implicated in liver...

Yan-Ruide Li, Xin-Yuan Shen, Yi-Chen Zhu et al. · 1 citation
Open access Sep 2026

Engineered probiotics for tumor-targeted combination chemoimmunotherapy

The approach integrates enzyme/prodrug therapy and immunotherapy into a single bacterial delivery system, overcoming key limitations of conventional therapies by providing a rationally designed framework for spatially controlled chemoimmunotherapy.

Zao-Feng Yang, Jong-Seong Im, Noah Chen et al. · 0 citations
Review Open access Sep 2026

Effector-cell-engaging bispecific antibodies for cancer therapeutics: engineering precision immunity.

This review outlines the evolution of effector-cell-engaging bsAb formats, such as BiTEs, DARTs, TandAbs and IgG-like constructs, along with engineering strategies to enhance Fc function, valency, half-life, safety and efficacy.

A. Gholap, P. Khuspe, Darshana Morankar et al. · 0 citations
Review Oct 2026

Reprogramming the Myeloid-T Cell Ecosystem through Engineered Oncolytic Viruses for Durable Antitumor Immunity.

Oncolytic virotherapy (OVT) has emerged as a promising immunotherapeutic strategy that combines selective tumor destruction with systemic immune activation. However, durable clinical responses remain limited because current approaches largely focus on viral replication and oncolysis while overlooking the immune network...

Chuan-Jian Wu, Wang-Lu Gu, An-Dong Qin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.